LE WE PMID CA
Antibodies (therapeutic use)178Antikoerper (therapeutische)

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alemtuzumab ttCD52

ALX0651 ttCXCR4

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (bispecific)

Antibodies (therapeutic use)

Atacicept ttBlys ttAPRIL

Autoantibodies (Therapeutic)

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Bi20 ttCD20

Blinatumomab ttCD19

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

BT062 ttCD138

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

CNS (Blood brain barrier)

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Drug development

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Ertumaxomab ttHER2

Etanercept ttTNFalpha

Eye (Pharmacology)

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

G Protein coupled receptor

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Ibritumomab tiuxentan yttrium ttCD20

IMGN901 ttCD56

Immune system (Toxicology)

Immunological methods

Infliximab ttTNFalpha

Ipilimumab ttCTLA4

KW0761 AMG761 ttCCR4

MDX1338 ttCXCR4

MLN1201 ttCCR2

MLN1202 ttCCR2

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pertuzumab ttHER2

PRO140 ttCCR5

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

Receptor (EGF)

REGN88 ttIL6R

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

Saporin s6

Solanezumab ttAmyloidBeta

T1H ttCD6

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2005  
1
Recombinant bispecific antibodies for cancer therapy.
[15659107] Acta Pharmacol Sin 26(1): 1-9 (2005)
2009  
2
Immunotoxicity of monoclonal antibodies.
[20061816] MAbs 1(2): 104-11 (2009)
2009  
3
Engineered CH2 domains (nanoantibodies).
[20046570] MAbs 1(1): 26-8 (2009)
1987  
4
The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
[3301638] Immunol Cell Biol 65 ( Pt 2)(-): 111-25 (1987)
2005  
5
Immunotoxins and cancer therapy.
[16191416] Cell Mol Immunol 2(2): 106-12 (2005)
2007  
6
Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.
[17242688] Cell Res 17(2): 89-99 (2007)
2009  
7
Antibody engineering to develop new antirheumatic therapies.
[19490600] Arthritis Res Ther 11(3): 225 (2009)
2007  
8
Combination antibody-based cancer immunotherapy.
[17559424] Cancer Sci 98(9): 1297-302 (2007)
2000  
9
New approaches to antibody therapy.
[11156528] Oncogene 19(53): 6144-51 (2000)
2001  
10
From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies.
[11477276] Rheumatology (Oxford) 40(7): 724-38 (2001)
1991  
11
The advantage of protecting the antigen-binding site during antibody labeling.
[1988615] J Nucl Med 32(1): 122-3 (1991)
2003  
12
2010  
13
New antibody conjugates in cancer therapy.
[20953556] ScientificWorldJournal 10(-): 2070-89 (2010)
2010  
14
The next generation of antibody-drug conjugates comes of age.
[21034674] Discov Med 10(53): 329-39 (2010)
2009  
15
Therapeutic antibodies: successes, limitations and hopes for the future.
[19459844] Br J Pharmacol 157(2): 220-33 (2009)
2010  
16
2010  
17
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
[20028761] Clin Cancer Res 16(1): 11-20 (2010)
2002  
18
Radionuclide-antibody conjugates for single-cell cytotoxicity.
[11877748] Cancer 94(4 Suppl): 1215-23 (2002)
2002  
19
Choosing an optimal radioimmunotherapy dose for clinical response.
[11877757] Cancer 94(4 Suppl): 1275-86 (2002)
2009  
20
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy.
[19809433] Br J Cancer 101(11): 1807-12 (2009)
2009  
21
Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.
[19018667] Antioxid Redox Signal 11(5): 1123-37 (2009)
2006  
22
Advances in cancer therapy with radiolabeled monoclonal antibodies.
[17043623] Q J Nucl Med Mol Imaging 50(4): 248-64 (2006)
2004  
23
A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.
[15640788] Q J Nucl Med Mol Imaging 48(4): 251-7 (2004)
2004  
24
Design and manufacture of monoclonal antibodies for radioimmunotherapy.
[15640789] Q J Nucl Med Mol Imaging 48(4): 258-66 (2004)
2004  
25
Engineered single chain antibody fragments for radioimmunotherapy.
[15640791] Q J Nucl Med Mol Imaging 48(4): 279-88 (2004)
2004  
26
Radioimmunotherapy of prostate cancer.
[15640793] Q J Nucl Med Mol Imaging 48(4): 297-304 (2004)
2011  
27
Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.
[22069735] Toxins (Basel) 3(6): 697-720 (2011)
2010  
28
Toxin-based therapeutic approaches.
[22069564] Toxins (Basel) 2(11): 2519-83 (2010)
2010  
29
Targeted toxins in brain tumor therapy.
[22069569] Toxins (Basel) 2(11): 2645-62 (2010)
2011  
30
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2011  
31
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.
[21150307] MAbs 3(2): 153-60 (2011)
2011  
32
Engineering the variable region of therapeutic IgG antibodies.
[21406966] MAbs 3(3): 243-52 (2011)
2011  
33
Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.
[21822050] MAbs 3(5): 440-52 (2011)
2010  
34
Therapeutic antibodies directed at G protein-coupled receptors.
[20864805] MAbs 2(6): 594-606 (2010)
2010  
35
Metrics for antibody therapeutics development.
[20930555] MAbs 2(6): 695-700 (2010)
2010  
36
Have we overestimated the benefit of human(ized) antibodies?
[20935511] MAbs 2(6): 682-94 (2010)
2010  
37
Therapeutic antibodies in ophthalmology: old is new again.
[21358858] MAbs 2(2): 176-80 (2010)
2010  
38
Stability of IgG isotypes in serum.
[20404539] MAbs 2(3): 221-32 (2010)
2010  
39
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
[20421713] MAbs 2(3): 233-55 (2010)
2009  
40
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.
[20069754] MAbs 1(3): 247-53 (2009)
2009  
41
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
[20073127] MAbs 1(6): 539-47 (2009)
2009  
42
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
[20068398] MAbs 1(6): 590-9 (2009)
2009  
43
Antibody-maytansinoid conjugates for the treatment of myeloma.
[20068397] MAbs 1(6): 548-51 (2009)
2009  
44
Americas Antibody Congress: September 21-23, 2009, Washington, D.C.
[20068395] MAbs 1(6): 523-30 (2009)
2010  
45
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
[20697078] J Clin Oncol 28(28): 4390-9 (2010)
2009  
46
Monoclonal antibodies for cancer immunotherapy.
[19304016] Lancet 373(9668): 1033-40 (2009)
2011  
47
Therapeutic monoclonal antibodies.
[21720199] Keio J Med 60(2): 37-46 (2011)
2011  
48
Integrin targeted delivery of chemotherapeutics.
[21547159] Theranostics 1(-): 189-200 (2011)
2009  
49
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.
[19529959] Med Microbiol Immunol 198(3): 157-74 (2009)
2009  
50
Invited article: human natural autoantibodies in the treatment of neurologic disease.
[19349608] Neurology 72(14): 1269-76 (2009)
2011  
51
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
[21811090] Exp Mol Med 43(10): 539-49 (2011)
2007  
52
Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.
[19003000] Cytotechnology 55(2-3): 109-14 (2007)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Antikoerper (therapeutische)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia